Theingi Shunn, Mitchell Ashara, Petre Elena N, Ziv Etay, Sofocleous Constantinos T, Solomon Stephen B, Alexander Erica S
Division of Interventional Radiology, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Transl Lung Cancer Res. 2025 Jun 30;14(6):2309-2316. doi: 10.21037/tlcr-2025-112. Epub 2025 Jun 19.
Small cell lung cancer (SCLC) is a high-grade neuroendocrine carcinoma associated with early development of distant metastases, which portends a worse prognosis. The median survival of metastatic SCLC with standard treatment is only 9-11 months, with a 5-year survival of 1-2%. Patients with SCLC are often initially responsive to systemic therapies, but once they develop resistance to them, locoregional therapies like thermal ablation should be investigated for possible improvements in morbidity and mortality. This brief retrospective report evaluates six patients with SCLC liver metastases (LMs), treated in 11 thermal ablation sessions (radiofrequency ablation or microwave ablation). Technical success was achieved in all treatments (100%). After the first ablation, 3/7 ablated tumors had residual disease. Survival outcomes were determined using the Kaplan-Meier method. Median local tumor progression-free survival (LTPFS) was 2.9 [95% confidence interval (CI): 0.5-3.9] months. Median assisted LTPFS, defined as tumor control with subsequent retreatment, was 25.9 (95% CI: 8.3-not reported) months. Median overall survival (OS) was 14.3 months. There was one adverse event (1/11) of grade 1, according to the Common Terminology Criteria for Adverse Events version 5.0, fatigue within a month of ablation, which self-resolved. The results suggest that thermal ablation is safe for SCLC LMs. Although LTPFS was very modest, the long duration of assisted LTPFS and OS in this small, retrospective study suggests that thermal ablation may be a promising treatment option.
小细胞肺癌（SCLC）是一种高级别神经内分泌癌，与远处转移的早期发生相关，这预示着更差的预后。转移性SCLC接受标准治疗的中位生存期仅为9 - 11个月，5年生存率为1% - 2%。SCLC患者通常最初对全身治疗有反应，但一旦对这些治疗产生耐药性，就应研究热消融等局部区域治疗方法，以期改善发病率和死亡率。这份简短的回顾性报告评估了6例发生肝转移（LM）的SCLC患者，共进行了11次热消融治疗（射频消融或微波消融）。所有治疗均取得技术成功（100%）。首次消融后，7个消融肿瘤中有3个有残留病灶。采用Kaplan - Meier方法确定生存结果。中位局部肿瘤无进展生存期（LTPFS）为2.9[95%置信区间（CI）：0.5 - 3.9]个月。中位辅助LTPFS定义为通过后续再治疗实现肿瘤控制，为25.9（95%CI：8.3 - 未报告）个月。中位总生存期（OS）为14.3个月。根据不良事件通用术语标准第5.0版，有1例1级不良事件（1/11），即消融后1个月内出现疲劳，该症状自行缓解。结果表明，热消融对SCLC肝转移是安全的。尽管LTPFS非常有限，但在这项小型回顾性研究中，辅助LTPFS和OS的持续时间较长，表明热消融可能是一种有前景的治疗选择。
